Metropolitan Life Insurance CO Foghorn Therapeutics Inc. Transaction History

Metropolitan Life Insurance CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$5.37 - $8.84 $6,954 - $11,447	1,295 New	1,295 $9,000
Q4 2022 Jun 14, 2023	BUY	$5.44 - $9.46 $7,828 - $13,612	1,439 New	1,439 $9.18 Million
Q4 2022 Mar 30, 2023	SELL	$5.44 - $9.46 $984 - $1,712	-181 Reduced 11.17%	1,439 $9,000
Q4 2022 Feb 15, 2023	SELL	$5.44 - $9.46 $984 - $1,712	-181 Reduced 11.17%	1,439 $9,000
Q3 2022 Jun 14, 2023	BUY	$7.52 - $18.01 $12,182 - $29,176	1,620 New	1,620 $13.9 Million
Q2 2022 Jun 20, 2023	BUY	$8.48 - $16.84 $13,737 - $27,280	1,620 New	1,620 $22,000
Q1 2022 Jun 20, 2023	BUY	$8.87 - $22.1 $14,369 - $35,802	1,620 New	1,620 $24,000
Q1 2022 Mar 30, 2023	SELL	$8.87 - $22.1 $43,897 - $109,372	-4,949 Reduced 75.34%	1,620 $24,000
Q1 2022 May 12, 2022	SELL	$8.87 - $22.1 $43,897 - $109,372	-4,949 Reduced 75.34%	1,620 $25,000
Q4 2021 Jun 21, 2023	BUY	$10.79 - $22.87 $70,879 - $150,233	6,569 New	6,569 $150,000
Q3 2021 Jun 21, 2023	BUY	$8.33 - $15.02 $54,719 - $98,666	6,569 New	6,569 $91,000
Q3 2021 Mar 30, 2023	BUY	$8.33 - $15.02 $42,732 - $77,052	5,130 Added 356.5%	6,569 $91,000
Q3 2021 Nov 15, 2021	BUY	$8.33 - $15.02 $54,719 - $98,666	6,569 New	6,569 $92,000

32.7M

1.8K

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $336M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.